nach oben

Erschienen in:

10.07.2018

Imaging strategy in recurrent ovarian cancer: a practical review

verfasst von: Lucia Manganaro, Silvia Gigli, Amanda Antonelli, Matteo Saldari, Federica Tomao, Claudia Marchetti, Emanuela Anastasi, Andrea Laghi

Erschienen in: Abdominal Radiology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Ovarian cancer is one of the most aggressive gynaecologic malignancies in women worldwide. The lack of proper screening programs and the characteristic abdominal spreading with minimal clinical symptoms give rise of its high lethality. Most patients show advanced disease at diagnosis and have a poor prognosis. The surveillance of ovarian cancer patients after initial treatment is a challenging question in clinical practice and there is no consensus in literature about the most appropriate follow-up strategy for these women. The role of Imaging has become increasingly important, allowing to properly monitor patients, distinguishing the different relapse patterns, thus guiding the correct management and therapy. In this review, we report and analyze the scientific evidence about the role of the different imaging modalities now available in the follow-up strategy and management of Epithelial Ovarian Cancer patients with recurrent disease.

Ferlay J, Soerjomataram I, Dikshit R, et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:359–386CrossRef

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259CrossRefPubMed

Chi DS, Eisenhauer EL, Lang J, et al. (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559–564CrossRefPubMed

Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371–1382CrossRefPubMed

Heintz APM, Odicino F, Maisonneuve P, et al. (2006) Carcinoma of the ovary. Int J Gynecol Obstet 95:161–192CrossRef

Dao MD, Alwan LM, Gray HJ, et al. (2013) Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 130:295–299. https://doi.org/10.1016/j.ygyno.2013.04.055 CrossRefPubMedPubMedCentral

Tsumura N, Sakuragi N, Hareyama H, et al. (1998) Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer 79:526–530CrossRefPubMed

Kimio U (2009) Treatment for recurrent ovarian cancer—at first relapse. J Oncol 2010:497429

Usami T, Kato K, Taniguchi T, et al. (2014) Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery. Int J Gynecol Cancer 24:991–996CrossRefPubMed

10.

Pignata S, Cannella L, Leopardo D, Bruni GS, Facchini G (2011) Pisano C (2011) Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol 22:viii40–viii44. https://doi.org/10.1093/annonc/mdr470 CrossRefPubMed

11.

Mitchell DG, Javitt MC, Glanc P, et al. (2013) American college of radiology. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol 10:822–827CrossRefPubMed

12.

Diaz-Gil D, Fintelmann FJ, Molaei S, et al. (2016) Prediction of 5-year survival in advanced-stage ovarian cancer patients based on computed tomography peritoneal carcinomatosis index. Abdom Radiol 41:2196–2202CrossRef

13.

Wrobel JK, Toborek M (2016) Blood-brain barrier remodeling during brain metastasis formation. Mol Med . https://doi.org/10.2119/molmed.2015.00207 CrossRefPubMedPubMedCentral

14.

Zola P, Macchi C, Cibula D, et al. (2015) Follow-up in gynecological malignancies a state of art. Int J Gynecol Cancer 25:1151–1164. https://doi.org/10.1097/IGC.0000000000000498 CrossRefPubMed

15.

Testa AC, Fruscella E, Ludovisi M, et al. (2005) The role of sonographic examination in the follow-up of gynecological neo- plasms. Gynecol Oncol 99:696–703CrossRefPubMed

16.

Gadducci A, Cosio S (2009) Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol 71:43–52CrossRefPubMed

17.

Zikan M, Fischerova D, Pinkavova I, Dundr P, Cibula D (2010) Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology. Ultrasound Obstet Gynecol 36:767–772CrossRefPubMed

18.

Kinkel K, Hricak H, Lu Y, Tsuda K, Filly RA (2000) US characterization of ovarian masses: a meta-analysis. Radiology 217:803–811CrossRefPubMed

19.

Testa AC, Di Legge A, Virgilio B, et al. (2014) Which imaging technique should we use in the follow up of gynaecological cancer? Best Pract Res Clin Obs Gyn 28:769–791CrossRef

20.

Hanbidge AE, Lynch D, Wilson SR (2003) US of the peritoneum. RadioGraphics 23:663–685CrossRefPubMed

21.

Woodward PJ, Hosseinzadeh K, Saenger JS (2004) Radiologic staging of ovarian carcinoma with pathologic correlation. RadioGraphics 24:225–246CrossRefPubMed

22.

Kawamoto S, Urban BA, Fishman EK (1999) CT of epithelial ovarian tumors. RadioGraphics 19:S85–S102CrossRefPubMed

23.

Urban BA, Fishman EK (1995) Spiral CT of the female pelvis: clinical applications. Abdom Imaging 20:9–14CrossRefPubMed

24.

Pannu HK, Bristow RE, Montz FJ, Fishman EK (2003) Multidetector CT of peritoneal carcinomatosis from ovarian cancer. RadioGraphics 23:687–701CrossRefPubMed

25.

Forstner R, Sala E, Kinkel K, Spencer JA (2010) European society of urogenital radiology. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 20:2773–2780CrossRefPubMed

26.

Kurtz AB, Tsimikas JV, Tempany CM, et al. (1999) Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis—report of the Radiology Diagnostic Oncology Group. Radiology 212:19–27CrossRefPubMed

27.

Arai K, Makino H, Morioka T, et al. (1993) Enhancement of ascites on MRI following intravenous administration of Gd-DTPA. J Comput Assist Tomogr 17:617–622CrossRefPubMed

28.

Kim CK, Park BK, Choi JY, Kim BG, Han H (2007) Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr 6:868–875CrossRef

29.

Low RN, Duggan B, Barone RM, et al. (2005) Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology 235:918–926CrossRefPubMed

30.

Hameeduddin A, Sahdev A (2015) Diffusion-weighted imaging and dynamic contrast-enhanced MRI in assessing response and recurrent disease in gynaecological malignancies. Cancer Imaging 15:3. https://doi.org/10.1186/s40644-015-0037-1 CrossRefPubMedPubMedCentral

31.

Ricke J, Sehouli J, Hach C, et al. (2003) Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 13:943–949CrossRefPubMed

32.

Sala E, Rockall AG, Freeman SJ, et al. (2013) The Added Role of MR Imaging in Treatment Stratification of Patients with Gynecologic Malignancies: what the Radiologist Needs to Know. Radiology 266:717–740. https://doi.org/10.1148/radiol.12120315 CrossRefPubMed

33.

Michielsen KL, Vergote I, Dresen R, et al. (2016) Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. Br J Radiol 89(1067):20160468CrossRefPubMedPubMedCentral

34.

Michielsen K, Dresen R, Vanslembrouck R, et al. (2017) Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer 83:88–98CrossRefPubMed

35.

Kyriazi S, Collins DJ, Morgan VA, Giles SL, deSouza NM (2010) Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. RadioGraphics. 30:1269–1285. https://doi.org/10.1148/rg.305105073 CrossRefPubMed

36.

Fehniger J, Thomas S, Lengyel E, et al. (2016) A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol 142:169e75CrossRef

37.

Espada M, Garcia-Flores JR, Jimenez M, et al. (2013) Diffusion-weighted magnetic resonance imaging evaluation of intraabdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma. Eur Radiol 23(2636):e42

38.

Nakai G, Matsuki M, Yn Inada, et al. (2008) Detection and evaluation of pelvic lymph nodes in patients with gynecologic malignancies using body diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr 32:764–768CrossRefPubMed

39.

Lin G, Ho KC, Wang JJ, et al. (2008) Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging 28:128–135CrossRefPubMed

40.

Kim JK, Kim KA, Park BW, et al. (2008) Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. Magn Reson Imaging 28:714–719CrossRef

41.

Park SO, Kim JK, Kim KA, et al. (2009) Relative apparent diffusion coefficient: determination of reference site and validation of benefit for detecting metastatic lymph nodes in uterine cervical cancer. J Magn Reson Imaging 29:383–390CrossRefPubMed

42.

Levy A, Medjhoul A, Caramella C, et al. (2011) Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: a review. J Magn Reson Imaging 33:1020–1027. https://doi.org/10.1002/jmri.22546 CrossRefPubMed

43.

Clavo AC, Brown RS, Wahl RL (1995) Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 36:1625–1632PubMed

44.

Fularz M, Adamiak P, Czepczyński R, et al. (2010) Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? Eur J Nucl Med Mol Imaging 37:1259–1269CrossRef

45.

Cho SM, Ha HK, Byun JY, et al. (2002) Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am J Roentgenol. 179:391–395CrossRefPubMed

46.

Kim TH, Kim J, Kang YK, et al. (2017) Identification of metabolic biomarkers using serial ¹⁸F-FDG PET/CT for prediction of recurrencein advanced epithelial ovarian cancer. Transl Oncol 10:297–303. https://doi.org/10.1016/j.tranon.2017.02.001 CrossRefPubMedPubMedCentral

47.

Gu P, Pan LL, Wu SQ, et al. (2009) CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 71:164–174CrossRefPubMed

48.

Satoh Y, Ichikawa T, Motosugi U, et al. (2011) Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDC. AJR 196:447–453CrossRefPubMed

49.

Suppiah S, Chang WL, Hassan HA, et al. (2017) Systematic review on the accuracy of positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging in the management of ovarian cancer: is functional information really needed? World J Nucl Med 16:176–185CrossRefPubMedPubMedCentral

50.

Limei Z, Yong C, Yan X, et al. (2013) Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer 23:598–607. https://doi.org/10.1097/IGC.0b013e31828a183c CrossRefPubMed

51.

Yuan Y, Gu ZX, Tao XF, Liu SY (2012) Computed tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. Eur J Radiol 81:1002–1006CrossRefPubMed

52.

Sebastian S, Lee SI, Horowitz NS, et al. (2008) PET–CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 33:112–118. https://doi.org/10.1007/s00261-007-9218-0 CrossRefPubMed

53.

Cook GJR (2010) PET and PET/CT imaging of skeletal metastases. Cancer Imaging 10:153–160. https://doi.org/10.1102/1470-7330.2010.0022 CrossRefPubMedCentral

54.

Mangili G, Picchio M, Sironi S, et al. (2007) Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 34(5):658–666. https://doi.org/10.1007/s00259-006-0306-0 CrossRefPubMed

55.

Simcock B, Neesham D, Quinn M, et al. (2006) The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 103(1):271–276CrossRefPubMed

56.

Fulham MJ, Carter J, Baldey A, et al. (2009) The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 112(3):462–468. https://doi.org/10.1016/j.ygyno.2008.08.027 CrossRefPubMed

57.

Han EJ, Park HL, Lee YS, et al. (2016) Clinical usefulness of post-treatment FDG PET/CT in patients with ovarian malignancy. Ann Nucl Med 30(9):600–607CrossRefPubMed

58.

Schwenzer NF, Schmidt H, Gatidis S, et al. (2014) Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET. J Magn Reson Imaging 40:1121–1128. https://doi.org/10.1002/jmri.24497 CrossRefPubMed

59.

Subhas N, Patel PV, Pannu HK, et al. (2005) Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. RadioGraphics 25:1031–1043CrossRefPubMed

60.

Levy T, Weiser R, Boaz M, et al. (2013) The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol Oncol 129:165–168CrossRefPubMed

61.

Song MJ, Lee SH, Choi MR, et al. (2013) Diagnostic value of CA125 as a predictor of recurrence in advanced ovarian cancer. Eur J Gynaecol Oncol 34:148–151PubMed

62.

Zimny M, Siggelkow W, Schröder W, et al. (2001) 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83:310–315CrossRefPubMed

63.

Sheng XG, Zhang XL, Fu Z, et al. (2007) Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 42:460–463PubMed

64.

Evangelista L, Palma MD, Gregianin M, et al. (2015) Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. J Turk Ger Gynecol Assoc 16:137–144CrossRefPubMedPubMedCentral

65.

Catalano OA, et al. (2013) Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study. Radiology 269:857–869. https://doi.org/10.1148/radiol.13131306 CrossRefPubMed

66.

Drzezga A (2012) First clinical experience with integrated whole body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53:845–855. https://doi.org/10.2967/jnumed.111.09860 CrossRefPubMed

67.

Parikh N, Friedman KP, Shah SN, Chandarana H (2015) Practical guide for implementing hybrid PET/MR clinical service: lessons learned from our experience. Abdom Imaging 40:1366–1373. https://doi.org/10.1007/s00261-015-0444-6 CrossRefPubMedPubMedCentral

68.

Grueneisen J, Schaarschmidt BM, Heubner M, et al. (2015) Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: a comparison to PET/CT. Eur J Radiol 84:2097–2102CrossRefPubMed

69.

Salani R, Khanna N, Frimer M, et al. (2017) An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 146:3–10CrossRefPubMed

70.

Morgan RJ, Alvarez RD, Armstrong DK, et al. (2013) Ovarian cancer, version 2.2013. J Natl Compr Cancer Netw 11:1199–1209CrossRef

Titel: Imaging strategy in recurrent ovarian cancer: a practical review
verfasst von: Lucia Manganaro
Silvia Gigli
Amanda Antonelli
Matteo Saldari
Federica Tomao
Claudia Marchetti
Emanuela Anastasi
Andrea Laghi
Publikationsdatum: 10.07.2018
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 3/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-018-1677-y

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Imaging strategy in recurrent ovarian cancer: a practical review

Abstract

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Beaded bile ducts in primary sclerosing cholangitis

The honeycomb pattern of pancreatic serous cystadenoma

The LACSEMS: what radiologists need to know

The “zebra spleen”

Comparative accuracy of qualitative and quantitative 18F-FDG PET/CT analysis in detection of lymph node metastasis from anal cancer

PET/CT in brachytherapy early response evaluation of pancreatic ductal adenocarcinoma xenografts: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie